Has Ian de Boer received payments from drug or device companies?

Yes. Drug and device makers reported $117,464 in general payments to Ian de Boer across 53 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ian de Boer did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ian de Boer come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ian de Boer

Nephrology · Seattle, WANPI 1932146669

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $95,719 of the $117,464 with a category attached, or 81.5%. It is spread thinly across 14 manufacturers, the largest accounting for just 22.3%. 2025 is the largest year on record at $29,513, 3.2 times the $9,151 reported in 2019. Among nephrology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$117,464in general payments, 2019–2025

Across 53 payments — averaging $2216.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim International GmbH$26K
Novo Nordisk AS$23K
Lexicon Pharmaceuticals, Inc.$16K
Eli Lilly$15K
Alnylam Pharmaceuticals Inc.$8K
Gilead$7K
plus $22K from 8 others

$281,682in research payments, 2019–2025

Across 23 payments — averaging $12,247 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk$202K
Dexcom, Inc.$50K
Novo Nordisk AS$29K

What the payments were for

Consulting fees$95,71981%
Travel & lodging$20,86418%
Food & beverage$8811%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim International GmbH	11	$26,189
Novo Nordisk AS	14	$22,747
Lexicon Pharmaceuticals, Inc.	3	$16,288
Eli Lilly	7	$14,918
Alnylam Pharmaceuticals Inc.	1	$8,120
Gilead	3	$7,310
Boehringer Ingelheim	4	$4,927
GSK	2	$4,550
Roche Products Limited	1	$3,930
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$2,720
F. Hoffmann-la Roche AG	1	$2,620
AstraZeneca	3	$2,518
Astrazeneca UK Limited	1	$490
Dexcom, Inc.	1	$138

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,464 in reported general payments places this provider in the 95th percentile of 237 nephrology providers in Washington.

See all nephrology providers in Washington →

Other nephrology in Seattle

Osama AmroSeattle$395K
Nicolae LecaSeattle$101K
Syeda AhmadSeattle$68K
Stuart ShanklandSeattle$10K
Anne PesensonSeattle$10K
Lisa NakamotoSeattle$9K
Nisha BansalSeattle$8K
Michael TekesteSeattle$6K
Sarah SanghaviSeattle$4K
Bryan KestenbaumSeattle$4K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →